David M Taylor

Summary

Affiliation: South London and Maudsley NHS Trust
Country: UK

Publications

  1. ncbi Prolongation of QTc interval and antipsychotics
    David M Taylor
    Am J Psychiatry 159:1062; author reply 1064. 2002
  2. ncbi Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice
    David M Taylor
    Pharmacy Department, Maudsley Hospital, London, UK
    J Clin Psychiatry 70:196-200. 2009
  3. doi Effect of paliperidone palmitate on hospitalisation in a naturalistic cohort - a four-year mirror image study
    D M Taylor
    Maudsley Hospital, Pharmacy Department, Denmark Hill, London SE5 8AZ, UK Institute of Pharmaceutical Science, King s College, 5th Floor, Franklin Wilkins Building, 150 Stamford Street, London SE1 9NH, UK Electronic address
    Eur Psychiatry 37:43-8. 2016
  4. doi Paliperidone palmitate: factors predicting continuation with treatment at 2 years
    David M Taylor
    Maudsley Hospital, Pharmacy Department, Denmark Hill, London SE5 8AZ, UK Institute of Pharmaceutical Science, King s College, London, 5th Floor, Franklin Wilkins Building 150 Stamford Street, London SE1 9NH, UK Electronic address
    Eur Neuropsychopharmacol 26:2011-2017. 2016
  5. pmc Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression
    Brian Leonard
    Department of Pharmacology, National University of Ireland, Galway, Ireland
    J Psychopharmacol 24:1143-52. 2010
  6. pmc Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies
    David Taylor
    King s College London, Institute of Pharmaceutical Science, London SE1 9NH, UK
    BMJ 348:g1888. 2014
  7. pmc Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study
    R John Dobbs
    Pharmaceutical Science, King s College London, Franklin Wilkins Building, 150 Stamford Street, London SE1 9NH, UK
    Gut Pathog 4:12. 2012
  8. pmc Behavioral interventions for antipsychotic induced appetite changes
    Ursula Werneke
    Department of Clinical Sciences, Division of Psychiatry, Umea University, 90185 Umea, Sweden
    Curr Psychiatry Rep 15:347. 2013
  9. ncbi A controlled, mirror-image study of second-generation antipsychotics in the treatment of schizophrenia
    David Taylor
    Pharmacy Department, Maudsley Hospital, London, UK
    Int Clin Psychopharmacol 22:133-6. 2007
  10. doi Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review
    David Taylor
    Pharmacy Department, Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK
    Br J Psychiatry Suppl 52:S13-9. 2009

Collaborators

Detail Information

Publications41

  1. ncbi Prolongation of QTc interval and antipsychotics
    David M Taylor
    Am J Psychiatry 159:1062; author reply 1064. 2002
  2. ncbi Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice
    David M Taylor
    Pharmacy Department, Maudsley Hospital, London, UK
    J Clin Psychiatry 70:196-200. 2009
    ..To evaluate outcomes of clinical use of risperidone long-acting injection (RLAI) and determine factors predicting continuation with treatment...
  3. doi Effect of paliperidone palmitate on hospitalisation in a naturalistic cohort - a four-year mirror image study
    D M Taylor
    Maudsley Hospital, Pharmacy Department, Denmark Hill, London SE5 8AZ, UK Institute of Pharmaceutical Science, King s College, 5th Floor, Franklin Wilkins Building, 150 Stamford Street, London SE1 9NH, UK Electronic address
    Eur Psychiatry 37:43-8. 2016
    ..Clinical trial outcomes are heavily influenced by the non-naturalistic clinical trial process. Observations of outcomes in clinical practice are a valuable adjunct to clinical trial results...
  4. doi Paliperidone palmitate: factors predicting continuation with treatment at 2 years
    David M Taylor
    Maudsley Hospital, Pharmacy Department, Denmark Hill, London SE5 8AZ, UK Institute of Pharmaceutical Science, King s College, London, 5th Floor, Franklin Wilkins Building 150 Stamford Street, London SE1 9NH, UK Electronic address
    Eur Neuropsychopharmacol 26:2011-2017. 2016
    ..05, 2.51 p=0.028)). The rate of continuation with PP at 2 years was higher than that seen with other long acting depot formulations. Likelihood of continuation can be vastly improved by targeting PP for those most likely to benefit...
  5. pmc Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression
    Brian Leonard
    Department of Pharmacology, National University of Ireland, Galway, Ireland
    J Psychopharmacol 24:1143-52. 2010
    ..Escitalopram may have a favourable benefit-risk ratio compared with citalopram and possibly with several other antidepressant agents...
  6. pmc Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies
    David Taylor
    King s College London, Institute of Pharmaceutical Science, London SE1 9NH, UK
    BMJ 348:g1888. 2014
    ..To systematically review published and unpublished efficacy studies of agomelatine in people with depression...
  7. pmc Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study
    R John Dobbs
    Pharmaceutical Science, King s College London, Franklin Wilkins Building, 150 Stamford Street, London SE1 9NH, UK
    Gut Pathog 4:12. 2012
    ..Small intestinal bacterial-overgrowth (SIBO) is a candidate driver of the rigidity: hydrogen-breath-test-positivity is common in IP and case histories suggest that Helicobacter keeps SIBO at bay...
  8. pmc Behavioral interventions for antipsychotic induced appetite changes
    Ursula Werneke
    Department of Clinical Sciences, Division of Psychiatry, Umea University, 90185 Umea, Sweden
    Curr Psychiatry Rep 15:347. 2013
    ..In view of our currently rather limited treatment repertoire it seems timely systematically to explore such novel options...
  9. ncbi A controlled, mirror-image study of second-generation antipsychotics in the treatment of schizophrenia
    David Taylor
    Pharmacy Department, Maudsley Hospital, London, UK
    Int Clin Psychopharmacol 22:133-6. 2007
    ..Switching from one first-generation antipsychotic drug to another did not significantly affect number of days in hospital...
  10. doi Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review
    David Taylor
    Pharmacy Department, Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK
    Br J Psychiatry Suppl 52:S13-9. 2009
    ..Depot antipsychotics are widely used in clinical practice. Long-acting formulations of second-generation antipsychotics are now being developed and introduced...
  11. doi Risperidone long-acting injection: factors associated with changes in bed stay and hospitalisation in a 3-year naturalistic follow-up
    D Taylor
    Department of Pharmacy, Maudsley Hospital, London, UK, Pharmaceutical Sciences Division, King s College, London, UK
    J Psychopharmacol 24:995-9. 2010
    ..This and other analyses of the same patient cohort indicate that RLAI produces most favourable outcomes in outpatients and those not previously treated with clozapine...
  12. ncbi A prospective 6-month analysis of the naturalistic use of aripiprazole - factors predicting favourable outcome
    D Taylor
    Department of Pharmacy, Maudsley Hospital, London, UK
    Acta Psychiatr Scand 116:461-6. 2007
    ..To evaluate the effectiveness of aripiprazole in clinical practice...
  13. doi Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study
    David Taylor
    South London and Maudsley NHS Foundation Trust, Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK
    Eur Psychiatry 23:336-43. 2008
    ..To evaluate quality of life and patient preference for schizophrenia treatment in a community based study comparing the use of aripiprazole to the standard of care (SOC)...
  14. doi Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use
    D Taylor
    Pharmacy Department, Maudsley Hospital, London, UK
    Acta Psychiatr Scand 120:97-101. 2009
    ..To evaluate naturalistic use of risperidone long-acting injection (RLAI) and its effect on healthcare resource use...
  15. doi Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety
    D Taylor
    Pharmacy Department, Maudsley Hospital and Division of Pharmaceutical Sciences, King s College, London, UK
    Acta Psychiatr Scand 118:434-42. 2008
    ..To review data examining the relationships between depression, antidepressants and cardiovascular disease...
  16. doi Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies
    D M Taylor
    Pharmacy Department, South London and Maudsley NHS Foundation Trust, UK
    Acta Psychiatr Scand 119:419-25. 2009
    ..Aims of the study were to evaluate the therapeutic effect of adding an antipsychotic drug to clozapine treatment...
  17. ncbi Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome
    David M Taylor
    Pharmacy Department, Maudsley Hospital, London, UK
    Int J Neuropsychopharmacol 9:685-94. 2006
    ..61, p=0.001). Overall outcome of RLAI treatment is moderately good but better still when prescribed because of prior poor adherence and for more elderly patients. RLAI is less suitable for those who have previously received clozapine...
  18. ncbi Antidepressant withdrawal symptoms-telephone calls to a national medication helpline
    David Taylor
    Pharmacy Department, Maudsley Hospital, London SE5 8AZ, United Kingdom
    J Affect Disord 95:129-33. 2006
    ..All calls reporting symptoms of antidepressant withdrawal were noted from a retrospective examination of contemporaneous handwritten records...
  19. doi Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection
    David M Taylor
    Pharmacy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AZ, UK
    Br J Psychiatry 194:165-7. 2009
    ..Clozapine has a range of serious adverse effects that may give rise to an increased risk of death...
  20. ncbi Antipsychotics and QT prolongation
    D M Taylor
    South London and Maudsley NHS Trust, Denmark Hill, London
    Acta Psychiatr Scand 107:85-95. 2003
    ..To evaluate literature relating to cardiac QT prolongation and the use of antipsychotic drugs...
  21. ncbi Ziprasidone in the management of schizophrenia : the QT interval issue in context
    David Taylor
    Pharmacy Department, Maudsley Hospital, London, UK
    CNS Drugs 17:423-30. 2003
    ....
  22. ncbi Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis
    David M Taylor
    Maudsley Hospital, Denmark Hill, London, UK
    J Clin Psychiatry 64:589-97. 2003
    ..This study was designed as a cost analysis study comparing costs and basic clinical outcomes of treatment with risperidone or olanzapine in a naturalistic setting...
  23. doi Augmentation of clozapine with a second antipsychotic - a meta-analysis
    D M Taylor
    Pharmacy Department, Maudsley Hospital, London, UK
    Acta Psychiatr Scand 125:15-24. 2012
    ..To examine using meta-analysis the effect of adding a second antipsychotic to established clozapine monotherapy...
  24. doi Pharmacological interventions for people with depression and chronic physical health problems: systematic review and meta-analyses of safety and efficacy
    David Taylor
    Pharmacy Department, South London and Maudsley NHS Foundation Trust, Pharmaceutical Sciences Division, King s College London, UK
    Br J Psychiatry 198:179-88. 2011
    ..Antidepressant drugs are widely used in the treatment of depression in people with chronic physical health problems...
  25. ncbi Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients
    David M Taylor
    Pharmacy Department, Maudsley Hospital, London, United Kingdom
    J Clin Psychiatry 65:1076-83. 2004
    ..The use of risperidone long-acting injection (RLAI) is reasonably well supported by controlled studies. Little is known about treatment outcomes in patients receiving RLAI in clinical practice...
  26. ncbi Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs
    David Taylor
    Pharmacy Department, Maudsley Hospital, London, UK
    J Psychopharmacol 19:182-6. 2005
    ..Importantly, database analyses may underestimate the true prevalence of diabetes in similar populations and erroneously ascribe increased risk to certain drug treatments...
  27. ncbi Prognostic indicators for early discontinuation of risperidone long-acting injection
    Maxine X Patel
    Division of Psychological Medicine, Institute of Psychiatry and GKT School of Medicine, De Crespigny Park, London, UK
    Int Clin Psychopharmacol 19:233-9. 2004
    ..RLAI discontinuation is high early on but subsequently tapers off. Preceding antipsychotic type (depot versus oral) is a stronger prognostic indicator than treatment refractoriness for RLAI discontinuation...
  28. ncbi Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review
    David M Taylor
    Maudsley Hospital, London, United Kingdom
    J Clin Psychiatry 64:30-4. 2003
    ..It is thought that only clozapine is likely to be effective in such cases and that other drugs are ineffective. We sought to discover prior patterns of antipsychotic prescribing in schizophrenic patients eventually prescribed clozapine...
  29. ncbi Outcome following clozapine discontinuation: a retrospective analysis
    James M Atkinson
    South London and Maudsley National Health Service NHS Trust, Pharmacy Department, Maudsley Hospital, London, United Kingdom
    J Clin Psychiatry 68:1027-30. 2007
    ..Our aim was to establish medium-term outcome in patients stopping clozapine in normal clinical practice...
  30. doi Plasma concentrations of quetiapine, N-desalkylquetiapine, o-desalkylquetiapine, 7-hydroxyquetiapine, and quetiapine sulfoxide in relation to quetiapine dose, formulation, and other factors
    Danielle S Fisher
    Toxicology Unit, Department of Clinical Biochemistry, Bessemer Wing, King s College Hospital NHS Foundation Trust, London, United Kingdom
    Ther Drug Monit 34:415-21. 2012
    ....
  31. doi Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?
    Azizah Attard
    Pharmacy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London, UK
    CNS Drugs 26:491-508. 2012
    ..Overall, recent real-world studies have done much to confirm prior observations from efficacy-based randomized, controlled trials...
  32. ncbi How effective is St John's wort? The evidence revisited
    Ursula Werneke
    Centre for the Economics in Mental Health, Institute of Psychiatry, London, United Kingdom
    J Clin Psychiatry 65:611-7. 2004
    ..However, 3 recently published large studies failed to demonstrate robust efficacy. Updated meta-analysis and assessment of publication bias may help determine the true effect of St. John's wort...
  33. doi Anticholinergic effect on cognition (AEC) of drugs commonly used in older people
    Delia Bishara
    Pharmacy Department, Maudsley Hospital, London, UK
    Int J Geriatr Psychiatry . 2016
    ..Use of anticholinergic drugs in older people is associated with increased risk of cognitive decline and of dementia and death...
  34. ncbi Aripiprazole: a review of its pharmacology and clinical use
    D M Taylor
    Maudsley Hospital, London, UK
    Int J Clin Pract 57:49-54. 2003
    ..Aripiprazole seems not to cause significant EPSE, hyperprolactinaemia, excessive weight gain or cardiac rhythm disturbance. Limited data suggest that aripiprazole is not associated with impaired glucose tolerance...
  35. ncbi Health resource utilization associated with switching to risperidone long-acting injection
    C L Young
    Pharmacy Department, Maudsley Hospital, London, UK
    Acta Psychiatr Scand 114:14-20. 2006
    ..Our aim was to assess the effect on bed stay of risperidone injection prescribed in normal clinical practice...
  36. ncbi Atypical antipsychotics and weight gain--a systematic review
    D M Taylor
    Maudsley Hospital, London, UK
    Acta Psychiatr Scand 101:416-32. 2000
    ..To review systematically data relating to weight changes with atypical antipsychotics...
  37. ncbi Aripiprazole in schizophrenia: consensus guidelines
    M J Travis
    Institute of Psychiatry, London, UK
    Int J Clin Pract 59:485-95. 2005
    ..The purpose of these guidelines is to outline the consensus reached by the Schizophrenia Innovation Working Group on best practice in prescribing and appropriate use of aripiprazole in the UK...
  38. ncbi Refractory schizophrenia and atypical antipsychotics
    D M Taylor
    Maudsley Hospital, London, UK
    J Psychopharmacol 14:409-18. 2000
    ..There is essentially no cogent evidence to support the use of any other atypical in refractory schizophrenia. Clozapine remains the drug of choice in this condition...
  39. pmc A UK audit of screening for the metabolic side effects of antipsychotics in community patients
    Thomas R E Barnes
    Department of Psychological Medicine, Imperial College Faculty of Medicine, Charing Cross Campus, London W6 8RP, UK
    Schizophr Bull 33:1397-403. 2007
    ....
  40. ncbi Vagal response varies with Valsalva maneuver technique: a repeated-measures clinical trial in healthy subjects
    Lu Fee Wong
    Emergency Department, Royal Melbourne Hospital, Parkville, Australia
    Ann Emerg Med 43:477-82. 2004
    ..This study aimed to compare the magnitude of the vagal reflexes initiated by 5 variations of the Valsalva maneuver technique (supine, supine with epigastric pressure, supine with leg raise, semirecumbent position, and sitting position)...
  41. ncbi Biokinetic models for the behaviour of carbon-14 from labelled compounds in the human body: can a single generic model be justified?
    David M Taylor
    Chemistry Department, Cardiff University, Cardiff, CF10 3TB, UK
    Radiat Prot Dosimetry 108:187-202. 2004
    ..However, a comparison of the biokinetic information indicates that the ICRP default model would not be reliable for the interpretation of bioassay data...